210 related articles for article (PubMed ID: 35167335)
1. Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I-IIIA Completely Resected Non-Small-Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update.
Pisters K; Kris MG; Gaspar LE; Ismaila N;
J Clin Oncol; 2022 Apr; 40(10):1127-1129. PubMed ID: 35167335
[No Abstract] [Full Text] [Related]
2. Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update.
Singh N; Daly ME; Ismaila N;
J Clin Oncol; 2023 Sep; 41(27):4430-4432. PubMed ID: 37471673
[No Abstract] [Full Text] [Related]
3. Systemic Therapy for Melanoma: ASCO Guideline Rapid Recommendation Update.
Seth R; Messersmith H; Funchain P;
J Clin Oncol; 2022 Jul; 40(21):2375-2377. PubMed ID: 35658488
[No Abstract] [Full Text] [Related]
4. Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update.
Moy B; Rumble RB; Carey LA;
J Clin Oncol; 2023 Feb; 41(6):1318-1320. PubMed ID: 36626701
[No Abstract] [Full Text] [Related]
5. Management of Metastatic Renal Clear Cell Cancer: ASCO Guideline Rapid Recommendation Update.
Singer EA; Rumble RB; Rathmell WK; Van Veldhuizen PJ;
J Clin Oncol; 2023 Nov; 41(33):5184-5186. PubMed ID: 37812756
[No Abstract] [Full Text] [Related]
6. Management and Care of Patients With Invasive Cervical Cancer: ASCO Resource-Stratified Guideline Rapid Recommendation Update.
Chuang LT; Temin S; Berek JS;
JCO Glob Oncol; 2022 Mar; 8():e2200027. PubMed ID: 35245079
[No Abstract] [Full Text] [Related]
7. Cancer Cachexia: ASCO Guideline Rapid Recommendation Update.
Roeland EJ; Bohlke K; Baracos VE; Smith TJ; Loprinzi CL;
J Clin Oncol; 2023 Sep; 41(25):4178-4179. PubMed ID: 37467399
[No Abstract] [Full Text] [Related]
8. Systemic Therapy Update on
Garje R; Rumble RB; Parikh RA;
J Clin Oncol; 2023 Nov; ():JCO2302128. PubMed ID: 37931186
[No Abstract] [Full Text] [Related]
9. Chemotherapy and Targeted Therapy for Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That Is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Rapid Recommendation Update.
Moy B; Rumble RB; Carey LA;
J Clin Oncol; 2022 Sep; 40(26):3088-3090. PubMed ID: 35926153
[No Abstract] [Full Text] [Related]
10. Systemic Therapy Update on
Garje R; Rumble RB; Parikh RA
J Clin Oncol; 2022 Nov; 40(31):3664-3666. PubMed ID: 36112960
[No Abstract] [Full Text] [Related]
11. Poly(ADP-Ribose) Polymerase Inhibitors in the Management of Ovarian Cancer: ASCO Guideline Rapid Recommendation Update.
Tew WP; Lacchetti C; Kohn EC;
J Clin Oncol; 2022 Nov; 40(33):3878-3881. PubMed ID: 36150092
[No Abstract] [Full Text] [Related]
12. Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer-Cyclin-Dependent Kinase 4 and 6 Inhibitors: ASCO Guideline Rapid Recommendation Update.
Freedman RA; Caswell-Jin JL; Hassett M; Somerfield MR; Giordano SH;
J Clin Oncol; 2024 Jun; 42(18):2233-2235. PubMed ID: 38768407
[No Abstract] [Full Text] [Related]
13. Immunotherapy in Patients With Locally Advanced Esophageal Carcinoma: ASCO Treatment of Locally Advanced Esophageal Carcinoma Guideline Rapid Recommendation Update.
Shah MA; Hofstetter WL; Kennedy EB;
J Clin Oncol; 2021 Oct; 39(28):3182-3184. PubMed ID: 34406872
[No Abstract] [Full Text] [Related]
14. Use of Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update.
Korde LA; Somerfield MR; Hershman DL;
J Clin Oncol; 2022 May; 40(15):1696-1698. PubMed ID: 35417251
[No Abstract] [Full Text] [Related]
15. Testing for
Burstein HJ; DeMichele A; Somerfield MR; Henry NL;
J Clin Oncol; 2023 Jun; 41(18):3423-3425. PubMed ID: 37196213
[No Abstract] [Full Text] [Related]
16. Abemaciclib With Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Rapid Recommendation Update.
Giordano SH; Freedman RA; Somerfield MR;
J Clin Oncol; 2022 Jan; 40(3):307-309. PubMed ID: 34878801
[No Abstract] [Full Text] [Related]
17. Adjuvant PARP Inhibitors in Patients With High-Risk Early-Stage HER2-Negative Breast Cancer and Germline
Tung NM; Zakalik D; Somerfield MR;
J Clin Oncol; 2021 Sep; 39(26):2959-2961. PubMed ID: 34343058
[No Abstract] [Full Text] [Related]
18. Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non-Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update.
Kris MG; Gaspar LE; Chaft JE; Kennedy EB; Azzoli CG; Ellis PM; Lin SH; Pass HI; Seth R; Shepherd FA; Spigel DR; Strawn JR; Ung YC; Weyant M
J Clin Oncol; 2017 Sep; 35(25):2960-2974. PubMed ID: 28437162
[TBL] [Abstract][Full Text] [Related]
19. Postoperative radiotherapy in stage II or IIIA completely resected non-small cell lung cancer: a systematic review and practice guideline.
Okawara G; Ung YC; Markman BR; Mackay JA; Evans WK;
Lung Cancer; 2004 Apr; 44(1):1-11. PubMed ID: 15013578
[TBL] [Abstract][Full Text] [Related]
20. Definitive and Adjuvant Radiotherapy in Locally Advanced Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline.
Bezjak A; Temin S; Franklin G; Giaccone G; Govindan R; Johnson ML; Rimner A; Schneider BJ; Strawn J; Azzoli CG
J Clin Oncol; 2015 Jun; 33(18):2100-5. PubMed ID: 25944914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
